Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840 · View on ClinicalTrials.gov ↗
Study Summary
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.
Conditions Studied
Interventions
- DRUG 5-Fluorouracil (5-FU)
- DRUG Oxaliplatin
- DRUG PF-08046050
- DRUG bevacizumab
- DRUG Leucovorin (LV)
Study Locations (20)
Arizona
- Mayo Clinic Hospital — Phoenix
- Mayo Clinic — Scottsdale
California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte
- IP Address: City of Hope Investigational Drug Services(IDS) — Duarte
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora
- University of Colorado Hospital — Aurora
Florida
- Florida Cancer Specialists — Orlando
- Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando
Maryland
- Sidney Kimmel Comprehensive Cancer at Johns Hopkins — Baltimore
- The Johns Hopkins University — Baltimore
Massachusetts
- Beth Israel Deaconess Medical Center — Boston
- Beth Israel Deaconess Medical Center — Boston
Minnesota
- Mayo Clinic Cancer Center — Rochester
- Mayo Clinic — Rochester
Tennessee
- Sarah Cannon Research Institute - Pharmacy — Nashville
- SCRI Oncology Partners — Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 914 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2030-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06131840
The ClinicalTrials.gov registry entry for NCT06131840 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 914 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 6 conditions, with Carcinoma, Non-Small-Cell Lung appearing as the primary indexed condition, and to 5 interventions — of which 5-Fluorouracil (5-FU) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06131840 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Arizona, California, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06131840 about?
NCT06131840 is a clinical study titled "A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors". This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts o...
What is the current status of trial NCT06131840?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 914 participants. The study started on 2023-11-20. Estimated completion is 2030-09-12.
What conditions does trial NCT06131840 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small-Cell Lung, Pancreatic Ductal Adenocarcinoma, Colorectal Neoplasms, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06131840?
The interventions under investigation include: 5-Fluorouracil (5-FU) (DRUG), Oxaliplatin (DRUG), PF-08046050 (DRUG), bevacizumab (DRUG), Leucovorin (LV) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06131840?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06131840 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.